CA2747998C - Safe desmopressin administration - Google Patents

Safe desmopressin administration Download PDF

Info

Publication number
CA2747998C
CA2747998C CA2747998A CA2747998A CA2747998C CA 2747998 C CA2747998 C CA 2747998C CA 2747998 A CA2747998 A CA 2747998A CA 2747998 A CA2747998 A CA 2747998A CA 2747998 C CA2747998 C CA 2747998C
Authority
CA
Canada
Prior art keywords
dispenser
desmopressin
composition
patient
spray
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2747998A
Other languages
English (en)
French (fr)
Other versions
CA2747998A1 (en
Inventor
Seymour Fein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acerus Pharmaceuticals USA LLC
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42168193&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2747998(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CA2747998A1 publication Critical patent/CA2747998A1/en
Application granted granted Critical
Publication of CA2747998C publication Critical patent/CA2747998C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/02—Sprayers or atomisers specially adapted for therapeutic purposes operated by air or other gas pressure applied to the liquid or other product to be sprayed or atomised
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/08—Inhaling devices inserted into the nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/08—Inhaling devices inserted into the nose
    • A61M15/085—Fixing means therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/27—General characteristics of the apparatus preventing use
    • A61M2205/276—General characteristics of the apparatus preventing use preventing unwanted use

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
CA2747998A 2008-12-22 2009-12-21 Safe desmopressin administration Active CA2747998C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13987108P 2008-12-22 2008-12-22
US61/139,871 2008-12-22
PCT/US2009/068962 WO2010075266A2 (en) 2008-12-22 2009-12-21 Safe desmopressin administration

Publications (2)

Publication Number Publication Date
CA2747998A1 CA2747998A1 (en) 2010-07-01
CA2747998C true CA2747998C (en) 2016-05-31

Family

ID=42168193

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2747998A Active CA2747998C (en) 2008-12-22 2009-12-21 Safe desmopressin administration

Country Status (19)

Country Link
US (4) US20120015880A1 (cg-RX-API-DMAC7.html)
EP (2) EP2381923B2 (cg-RX-API-DMAC7.html)
JP (4) JP5731396B2 (cg-RX-API-DMAC7.html)
KR (2) KR20170081711A (cg-RX-API-DMAC7.html)
CN (2) CN105963834A (cg-RX-API-DMAC7.html)
AU (1) AU2009330203B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0923557A2 (cg-RX-API-DMAC7.html)
CA (1) CA2747998C (cg-RX-API-DMAC7.html)
DK (1) DK2381923T4 (cg-RX-API-DMAC7.html)
EA (2) EA201791732A1 (cg-RX-API-DMAC7.html)
ES (1) ES2692345T5 (cg-RX-API-DMAC7.html)
IL (1) IL213699A (cg-RX-API-DMAC7.html)
MX (1) MX2011006765A (cg-RX-API-DMAC7.html)
NZ (1) NZ593613A (cg-RX-API-DMAC7.html)
PL (1) PL2381923T5 (cg-RX-API-DMAC7.html)
PT (1) PT2381923T (cg-RX-API-DMAC7.html)
SG (2) SG10201509152VA (cg-RX-API-DMAC7.html)
WO (1) WO2010075266A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201105420B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009021007A1 (en) 2007-08-06 2009-02-12 Serenity Pharmaceuticals Corporation Methods and devices for desmopressin drug delivery
SG10201509152VA (en) * 2008-12-22 2015-12-30 Allergan Inc Intranasal desmopressin administration
CA2765221C (en) * 2009-06-18 2017-10-03 Allergan, Inc. Safe desmopressin administration
EP3024473A1 (en) 2013-07-23 2016-06-01 Allergan, Inc. Methods and compositions comprising desmopressin in combination with a 5-alpha reductase inhibitor
CN105579057A (zh) * 2013-07-23 2016-05-11 阿勒根公司 包含与β-3-肾上腺素能受体激动剂组合的去氨加压素的方法和组合物
CA2967390A1 (en) 2014-11-20 2016-05-26 Allergan, Inc. Methods and compositions comprising desmopressin in combination with an alpha-adrenergic receptor antagonist

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS171787B1 (cg-RX-API-DMAC7.html) 1973-11-09 1976-11-29
US4148787A (en) 1976-05-24 1979-04-10 Ferring Ab Antidiuretically effective polypeptide and a process for preparing the same
US4771769A (en) 1982-12-20 1988-09-20 Schering Corporation Hand held metered spray dispenser
US4548922A (en) 1983-06-06 1985-10-22 Beth Israel Hospital Drug administration
US4746508A (en) 1983-06-06 1988-05-24 Beth Israel Hospital Assn. Drug administration
US5731303A (en) 1985-12-04 1998-03-24 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery compositions
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5112804A (en) 1987-04-01 1992-05-12 Temple University Of The Commonwealth System Of Higher Education Pharmaceutical composition and method of intranasal administration
US4944429A (en) 1987-08-28 1990-07-31 Schering Corporation Manually-operable spray dispenser with locking mechanism
US5154122A (en) 1989-10-20 1992-10-13 Sol Goldschmidt Shipping device for suspended piece goods
CN1060980A (zh) * 1990-10-26 1992-05-13 蔡东林 多用电控自控微型喷雾器
US5314694A (en) 1990-10-29 1994-05-24 Alza Corporation Transdermal formulations, methods and devices
US5122383A (en) 1991-05-17 1992-06-16 Theratech, Inc. Sorbitan esters as skin permeation enhancers
US5227169A (en) 1991-05-17 1993-07-13 Theratech, Inc. Sorbitan esters as skin permeation enhancers
US5212199A (en) 1991-05-17 1993-05-18 Theratech, Inc. Sorbitan esters as skin permeation enhancers
IT1255895B (it) 1992-10-20 1995-11-17 Laura Chiodini Composizioni farmaceutiche contenenti una calcitonina
DK0708657T3 (da) * 1993-06-29 2001-10-15 Ferring Bv Sammensætninger til nasal administration af desmopression
WO1996040332A1 (en) * 1995-06-07 1996-12-19 O'neil, Christine Patient controlled drug delivery device
US5763398A (en) * 1996-06-20 1998-06-09 Ferring B.V. Nasal administration of desmopressin
DE19723133A1 (de) 1997-06-03 1998-12-10 Caideil M P Teoranta Tourmakea Austragvorrichtung für Medien
US7335186B2 (en) 1998-03-13 2008-02-26 Alexander George Brian O'Neil Patient controlled drug delivery device
AU3421600A (en) 1999-02-14 2000-08-29 Ing. Erich Pfeiffer Gmbh Dispenser for flowable media
DE19938798A1 (de) 1999-08-16 2001-03-01 Pfeiffer Erich Gmbh & Co Kg Spender für Flüssigkeiten oder für zähflüssige oder versprühbare Produkte
DE19940236A1 (de) 1999-08-25 2001-03-08 Pfeiffer Erich Gmbh & Co Kg Spender mit manuell betätigbarer Ausbringeinrichtung
DE10110742A1 (de) 2001-02-28 2002-09-05 Pfeiffer Erich Gmbh & Co Kg Spender für Medien
US7244703B2 (en) 2001-06-22 2007-07-17 Bentley Pharmaceuticals, Inc. Pharmaceutical compositions and methods for peptide treatment
PL200833B1 (pl) 2001-09-21 2009-02-27 Pfeiffer Erich Gmbh & Co Kg Dozownik z pojemnikiem aplikowanego środka oraz pompka do dozownika
US20030232078A1 (en) 2001-12-19 2003-12-18 Dong Liang C. Formulation & dosage form for the controlled delivery of therapeutic agents
GB0210397D0 (en) * 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
ITMI20021684A1 (it) * 2002-07-29 2004-01-29 Therapicon Srl Composizione farmaceutica di peptide nasale
US7186692B2 (en) * 2002-12-17 2007-03-06 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity
WO2005046707A1 (en) * 2003-11-10 2005-05-26 Fein Seymour H Pharmaceutical compositions including low dosages of desmopressin
JP2007513199A (ja) * 2003-12-08 2007-05-24 ベントレー ファーマスーティカルス,インコーポレイテッド インスリン治療のための薬学的組成物及び方法
WO2007022345A2 (en) * 2005-08-17 2007-02-22 Fleming And Company, Pharmaceuticals Vitamin b12 nasal spray and method of use
CN1785448A (zh) * 2005-11-11 2006-06-14 广东工业大学 医用防染式药雾吸入喷嘴
EP2035031A4 (en) * 2006-06-08 2010-02-24 Cpex Pharmaceuticals Inc INSULIN COMPOSITION
SG10201509152VA (en) * 2008-12-22 2015-12-30 Allergan Inc Intranasal desmopressin administration
CA2765221C (en) 2009-06-18 2017-10-03 Allergan, Inc. Safe desmopressin administration

Also Published As

Publication number Publication date
JP2015127350A (ja) 2015-07-09
KR101755042B1 (ko) 2017-07-06
EA201170873A1 (ru) 2012-02-28
JP5959076B2 (ja) 2016-08-02
JP5731396B2 (ja) 2015-06-10
EA201791732A1 (ru) 2018-03-30
JP2012513403A (ja) 2012-06-14
AU2009330203A1 (en) 2011-07-14
IL213699A (en) 2016-05-31
DK2381923T4 (da) 2023-09-11
ZA201105420B (en) 2012-04-25
JP2016196488A (ja) 2016-11-24
CN105963834A (zh) 2016-09-28
EA028531B1 (ru) 2017-11-30
CN102355888A (zh) 2012-02-15
EP2381923A2 (en) 2011-11-02
JP6389209B2 (ja) 2018-09-12
SG10201509152VA (en) 2015-12-30
PL2381923T3 (pl) 2019-04-30
ES2692345T3 (es) 2018-12-03
MX2011006765A (es) 2011-11-01
KR20170081711A (ko) 2017-07-12
JP2018184407A (ja) 2018-11-22
PL2381923T5 (pl) 2024-08-26
NZ593613A (en) 2013-02-22
EP2381923B2 (en) 2023-06-07
CA2747998A1 (en) 2010-07-01
EP2381923B1 (en) 2018-08-01
US20200078542A1 (en) 2020-03-12
SG172344A1 (en) 2011-07-28
ES2692345T5 (es) 2024-01-26
US20120015880A1 (en) 2012-01-19
WO2010075266A3 (en) 2011-01-06
KR20110102915A (ko) 2011-09-19
BRPI0923557A2 (pt) 2016-01-26
IL213699A0 (en) 2011-07-31
WO2010075266A2 (en) 2010-07-01
US20240342407A1 (en) 2024-10-17
AU2009330203B2 (en) 2015-09-03
DK2381923T3 (en) 2018-11-19
EP3437633A1 (en) 2019-02-06
US20220126039A1 (en) 2022-04-28
PT2381923T (pt) 2018-11-13

Similar Documents

Publication Publication Date Title
US12090190B2 (en) Safe desmopressin administration
US20240342407A1 (en) Intranasal desmopressin administration
AU2015261630B2 (en) Intranasal desmopressin administration
HK40084952B (en) Safe desmopressin administration
HK40084952A (en) Safe desmopressin administration
HK40060414B (en) Safe desmopressin administration
HK40060414A (en) Safe desmopressin administration
HK1250642B (en) Safe desmopressin administration
HK1250642A1 (en) Safe desmopressin administration
HK1172544A (en) Safe desmopressin administration
HK1172544B (en) Safe desmopressin administration

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20141211

R00 Party data change recorded

Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R00-R116 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUEST

Effective date: 20240729

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R11-R103 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF NAME REQUEST RECEIVED

Effective date: 20240729

R00 Party data change recorded

Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R00-R119 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUEST

Effective date: 20241122

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241122

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 15TH ANNIV.) - STANDARD

Year of fee payment: 15

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241213

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241213

R13 Change to the name of applicant or owner recorded

Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R13-R104 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF NAME REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250612

R17 Change to representative recorded

Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R17-R121 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250616

Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R17-R117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250616

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250616

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260202

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260513

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260521

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260804